다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

ARGX

argenx (ARGX)

argenx SE

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ARGX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/06/11	19:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2025/06/11	07:01	GlobeNewswire Inc.	argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	NASDAQ:ARGX	argenx SE
2025/06/03	14:00	GlobeNewswire Inc.	argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference	NASDAQ:ARGX	argenx SE
2025/05/29	05:01	GlobeNewswire Inc.	argenx Announces Results of Annual General Meeting of Shareholders	NASDAQ:ARGX	argenx SE
2025/05/08	19:39	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2025/05/08	14:00	GlobeNewswire Inc.	argenx Reports First Quarter 2025 Financial Results and Provides Business Update	NASDAQ:ARGX	argenx SE
2025/05/06	14:00	GlobeNewswire Inc.	argenx to Present at BofA Securities 2025 Health Care Conference	NASDAQ:ARGX	argenx SE
2025/05/01	14:00	GlobeNewswire Inc.	argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025	NASDAQ:ARGX	argenx SE
2025/04/28	21:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2025/04/28	14:00	GlobeNewswire Inc.	argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	NASDAQ:ARGX	argenx SE
2025/04/12	05:01	GlobeNewswire Inc.	argenx Announces Annual General Meeting of Shareholders on May 27, 2025	NASDAQ:ARGX	argenx SE
2025/04/11	06:47	GlobeNewswire Inc.	argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy	NASDAQ:ARGX	argenx SE
2025/04/08	19:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2025/04/08	14:00	GlobeNewswire Inc.	argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP	NASDAQ:ARGX	argenx SE
2025/03/20	19:46	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:ARGX	argenx SE
2025/03/20	19:07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2025/03/07	20:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2025/03/07	15:00	GlobeNewswire Inc.	argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting	NASDAQ:ARGX	argenx SE
2025/02/27	20:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2025/02/27	15:00	GlobeNewswire Inc.	argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update	NASDAQ:ARGX	argenx SE
2025/02/25	15:00	GlobeNewswire Inc.	argenx to Present at TD Cowen 45th Annual Healthcare Conference	NASDAQ:ARGX	argenx SE
2025/02/20	15:00	GlobeNewswire Inc.	argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025	NASDAQ:ARGX	argenx SE
2025/02/12	23:16	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ARGX	argenx SE
2025/01/13	15:00	GlobeNewswire Inc.	argenx Highlights 2025 Strategic Priorities	NASDAQ:ARGX	argenx SE
2025/01/06	15:00	GlobeNewswire Inc.	argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:ARGX	argenx SE
2024/12/27	20:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/12/27	15:00	GlobeNewswire Inc.	argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy	NASDAQ:ARGX	argenx SE
2024/11/26	15:00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	NASDAQ:ARGX	argenx SE
2024/11/20	20:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/11/20	15:00	GlobeNewswire Inc.	argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies	NASDAQ:ARGX	argenx SE

검색 관련기사 보기:NASDAQ:ARGX

1 2 3 4 5 6 7 8 9 10 다음 >>

Energy Select Sector SPDR

US Dollar vs Sterling

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관